1,645,331 Elanco Animal Health Incorporated $ELAN Shares Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 55.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,611,977 shares of the company’s stock after purchasing an additional 1,645,331 shares during the period. Artemis Investment Management LLP owned 0.92% of Elanco Animal Health worth $103,262,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Sapient Capital LLC raised its position in Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock worth $3,164,000 after acquiring an additional 420 shares during the period. Bessemer Group Inc. increased its stake in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Elanco Animal Health by 4.2% during the first quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock worth $342,000 after purchasing an additional 579 shares in the last quarter. Empowered Funds LLC raised its position in shares of Elanco Animal Health by 7.1% during the 1st quarter. Empowered Funds LLC now owns 17,753 shares of the company’s stock worth $425,000 after purchasing an additional 1,177 shares during the last quarter. Finally, Anchor Investment Management LLC acquired a new position in shares of Elanco Animal Health during the 2nd quarter worth about $29,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. TD Cowen lifted their price target on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. UBS Group increased their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.70.

Insider Buying and Selling

In other news, Director Paul Herendeen bought 10,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $23.68 per share, with a total value of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares in the company, valued at $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lawrence Kurzius bought 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 63,198 shares of company stock valued at $1,473,109 in the last ninety days. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Trading Up 0.2%

NYSE:ELAN traded up $0.04 during trading hours on Thursday, hitting $22.40. The company had a trading volume of 812,932 shares, compared to its average volume of 5,639,358. Elanco Animal Health Incorporated has a 1 year low of $19.40 and a 1 year high of $27.98. The company has a market cap of $11.19 billion, a P/E ratio of -54.76, a P/E/G ratio of 1.60 and a beta of 1.70. The company has a 50-day moving average of $23.55 and a 200 day moving average of $23.65. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.